Literature DB >> 28366274

Pembrolizumab in advanced head and neck cancer.

Vicki Brower.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28366274     DOI： 10.1016/S1470-2045(17)30245-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

Review 1.  Cancer immunotherapy of patients with HIV infection.

Authors:  M Gonzalez-Cao; J Martinez-Picado; N Karachaliou; R Rosell; A Meyerhans
Journal:  Clin Transl Oncol       Date:  2018-11-17       Impact factor: 3.405

2.  Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.

Authors:  Casey Quinn; Louis P Garrison; Anja K Pownell; Michael B Atkins; Gérard de Pouvourville; Kevin Harrington; Paolo Antonio Ascierto; Phil McEwan; Samuel Wagner; John Borrill; Elise Wu
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

3.  CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.

Authors:  Boya Deng; Jae-Hyun Park; Lili Ren; Poh Yin Yew; Kazuma Kiyotani; Tatjana Antic; Kelly O'Connor; Peter H O'Donnell; Yusuke Nakamura
Journal:  Cancer Rep (Hoboken)       Date:  2018-04-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.